Oxford BioMedica Plc has stopped administering vaccinations to patients in a Phase 3 trial of its lead cancer product, TroVax, after an independent data safety monitoring board declared that the study would not meet its primary endpoint of overall survival in renal cancer. The study will be completed in order to collect follow-up data on patients. But the trial data alone will not be sufficient to support an application for a marketing authorisation in renal cancer, the company said on 11 July 2008.
